The latest report by IMARC Group, titled "RNA Interference (RNAi) Drug Delivery Market: Global Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2023-2028," finds that the global RNA interference (RNAi) drug delivery market size reached US$ 69.2 Billion in 2022. RNA interference (RNAi) is a biological process that regulates gene expression by inhibiting the production of specific proteins. It can be artificially induced through small interfering RNAs (siRNAs), which are double-stranded RNA molecules that target specific mRNA molecules, resulting in their degradation and subsequent inhibition of protein synthesis. It involves the development of technologies and strategies such as lipid nanoparticles, viral vectors, and polymer-based delivery systems to deliver siRNAs to specific cells and tissues in the body, where they can effectively inhibit target genes. Consequently, RNAi is widely used as a therapeutic approach for various diseases, including cancer, viral infections, and genetic disorders.
Global RNA Interference (RNAi) Drug Delivery Trends:
The market is primarily driven by the growing prevalence of chronic medical and genetic disorders, such as cancer and cardiovascular diseases (CVDs) among individuals. In addition, the growing geriatric population, which is more susceptible to such ailments, represents another major growth-inducing factor. Besides this, the outbreak of the coronavirus disease (COVID-19) has led to a surge in demand for RNAi drug delivery technologies and targeted delivery methods, such as aptamer drug delivery systems for administering antiviral drugs as they use small interfering RNA (siRNA) to inhibit viral antigen expression. This, coupled with the development of innovative synthetic delivery carriers and bio-vectors like nanocarriers, which include siRNA or microRNAs (miRNA), that are critical for creating personalized medicines and identifying altered cellular molecules and metabolites, is positively influencing the market growth. Moreover, extensive research and development (R&D) activities in the fields of nanotechnology and molecular diagnostics, and the developing healthcare infrastructure are also creating a positive market outlook across the globe. Looking forward, IMARC Group expects the market value to reach US$ 235.1 Billion by 2028, exhibiting a CAGR of 21.4% during 2023-2028.
- Based on the application, the market has been segmented into infectious disease, cardiology, oncology, neurology, ophthalmology, urology, metabolic disorders, and others.
- On the basis of technology, the market has been classified into nanoparticle, pulmonary, nucleic acid, and aptamer drug delivery.
- On the geographical front, the market has been divided into North America (the United States and Canada), Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others), Europe (Germany, France, the United Kingdom, Italy, Russia, Spain, and others), Latin America (Brazil, Mexico, and others), and the Middle East and Africa.
- The competitive landscape of the market has also been examined in the report, with some of the key players being Alnylam Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., CureVac AG, Dicerna Pharmaceuticals Inc., Gradalis Inc., Ionis Pharmaceuticals Inc, Merck & Co. Inc., Moderna Inc., Quark Pharmaceuticals Inc. (SBI ALApharma Co. Limited), Silence Therapeutics Plc and Sirnaomics Inc.
|Base Year of the Analysis
||Application, Technology, Region
|| Asia Pacific, Europe, North America, Latin America, Middle East and Africa
||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
||Alnylam Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., CureVac AG, Dicerna Pharmaceuticals Inc., Gradalis Inc., Ionis Pharmaceuticals Inc, Merck & Co. Inc., Moderna Inc., Quark Pharmaceuticals Inc. (SBI ALApharma Co. Limited), Silence Therapeutics Plc and Sirnaomics Inc
||10% Free Customization
|Report Price and Purchase Option
||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support
||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
134 N 4th St.
Brooklyn, NY 11249, USA
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800